Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Therapy with GLP-1 and GIP analogues is associated with certain side effects, the risk of developing macro- and micronutrient deficiencies, noticeable cosmetic defects and loss of muscle mass during rapid weight loss, and weight regain after discontinuation of therapy
Sources 1
Your ability to prescribe weight-loss medications independently depends on: Your states NP scope-of-practice laws (full practice, reduced practice, or restricted practice) Whether weight management falls within a PMHNPs specialty scope Specific state regulations on obesity treatment drugs In states like New York (after 3,600 practice hours), Illinois (with FPA application), Washington , and Arizona , NPs can prescribe weight-loss medications independently without physician oversight if its within their competency
Some GLP-1 drugs may be classified as Category B (for example, exenatide), which means animal studies have shown no harm to the fetus, but again, there is a lack of data in humans
In addition, upregulation of DRP1 contributed to mitochondrial fragmentation and levels of the mitochondrial fission protein DRP1 were increased in a mouse model of type 2 diabetes ( db/db mice) (Huang et al., 2015)
Merchenthaler IL, Lane M, Shughrue P (1999)
